Skip to main content



) --




) hit a new 52-week high Thursday as it is currently trading at $89.17, above its previous 52-week high of $89.16 with 157,165 shares traded as of 11:03 a.m. ET. Average volume has been 697,500 shares over the past 30 days.

Medivation has a market cap of $3.14 billion and is part of the

health care

sector and


industry. Shares are up 91.6% year to date as of the close of trading on Wednesday.

Scroll to Continue

TheStreet Recommends

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Medivation as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including poor profit margins and generally poor debt management. You can view the full

Medivation Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center